The latest clinical guidelines from the American College of Gastroenterology aim to improve the diagnosis and treatment of ...

Budesonide has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks. Additionally, the FDA recently approved dupilumab for pediatric patients aged one to ...

Some patients may exhibit clinical features of both gastroesophageal reflux disease (GERD) and EoE and therefore clinical judgment must be used to help decide on the appropriate treatment after ...

Adults younger than 65 years with esophageal cancer were extremely unlikely to have a previous diagnosis of eosinophilic ...

Topical steroids taken daily or twice daily do not result in significantly varying outcomes among individuals with eosinophilic esophagitis.

Considering “paradigm-shifting changes” in the diagnosis and management of eosinophilic esophagitis, the ACG released an updated guideline on treatment, monitoring and maintenance as well as ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

Discover top medications for 'treating Eosinophilic Esophagitis (EoE)'? This page compiles essential information on generic and brand-name drugs specifically used for Eosinophilic Esophagitis (EoE ...

Compared with female patients, male patients with eosinophilic esophagitis have higher rates of complications, including ...

The Eosinophilic Esophagitis market report provides current treatment practices, emerging drugs, Eosinophilic Esophagitis market share of individual therapies, and current and forecasted ...

The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...